AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12898044 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia
Number of subjects: 40
Study 12898044 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal arterial oxygen saturation (SatO(2))
Number of subjects: 40
Study 11860948 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with HFRS vaccine
Number of subjects: 26419
Study 11860948 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster immunization after one year
Number of subjects: 26419
Study 8970471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic HIV-1 vaccine
Number of subjects: 0
Study 8970471 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented designs for trials
Number of subjects: 0
Study 1622173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg orally every 8 h for the first 72 h and then every 12 h for a total of 10 days) plus a beta‐lactam agent plus an aminoglycoside
Number of subjects: 121
Study 1622173 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of a beta‐lactam plus an aminoglycoside agent
Number of subjects: 121
Study 6519163 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg orally
Number of subjects: 6
Study 6519163 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg intravenously
Number of subjects: 6
Study 31288532 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stapedotomy
Number of subjects: 64
Study 31288532 — intervention group
Group type: COMPARATOR
Intervention: Conventional stapedotomy using operating microscope
Number of subjects: 64
Study 30218805 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical resection alone
Number of subjects: 86
Study 30218805 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative embolization followed by microsurgical resection
Number of subjects: 86
Study 30218805 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery alone
Number of subjects: 86
Study 30218805 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization followed by stereotactic radiosurgery
Number of subjects: 86
Study 30218805 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization alone
Number of subjects: 86
Study 30218805 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 86
Study 28655079 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo‐radiotherapy
Number of subjects: 69
Study 28655079 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy only (CT)
Number of subjects: 69
Study 25931658 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training (PRET)
Number of subjects: 52
Study 25931658 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic protocol (TP)
Number of subjects: 52
Study 24026135 — intervention group
Group type: EXPERIMENTAL
Intervention: Voix d'Or(®) intervention
Number of subjects: 24
Study 24026135 — intervention group
Group type: COMPARATOR
Intervention: Usual occupational activities (Control)
Number of subjects: 24
Study 21378585 — intervention group
Group type: COMPARATOR
Intervention: Recombinant Factor VII (placebo-controlled)
Number of subjects: 347
Study 18180244 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD regimen followed by involved field radiotherapy
Number of subjects: 181
Study 18180244 — intervention group
Group type: COMPARATOR
Intervention: EVE regimen followed by involved field radiotherapy
Number of subjects: 181
Study 16384692 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins and soybean and fish oils supplementation
Number of subjects: 61
Study 16384692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 61
Study 16191248 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0
Study 11039963 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic needles
Number of subjects: 116
Study 11039963 — intervention group
Group type: COMPARATOR
Intervention: Standard needles
Number of subjects: 116
Study 8857476 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer-188 infusion for 48 hours
Number of subjects: 150
Study 8857476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8857476 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer-188 infusion
Number of subjects: 150
Study 1346790 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist, piribedil, at 50‐100 mg/day, orally, for 8 weeks
Number of subjects: 9
Study 1346790 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 agonist, bromocriptine, at 2.5 ‐ 5 mg/day, orally, for another 8 weeks
Number of subjects: 9
Study 1346790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6206718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion group (hemoglobin level kept above 10.0 g/dL)
Number of subjects: 56
Study 6206718 — intervention group
Group type: COMPARATOR
Intervention: Nontransfusion group (transfused only for specific clinical indications)
Number of subjects: 56
Study 31662555 — intervention group
Group type: EXPERIMENTAL
Intervention: Good RTL group (low LTF1)
Number of subjects: 92
Study 31662555 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate RTL group (high LTF1 and low LTF2)
Number of subjects: 92
Study 31662555 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor RTL group (high LTF1 and high LTF2)
Number of subjects: 92
Study 29936464 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyusho Jitsu intervention (24 weeks)
Number of subjects: 51
Study 29936464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 25737191 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 252
Study 25737191 — intervention group
Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 252
Study 24231216 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/d), tamsulosin (0.4 mg/d), saw palmetto (320 mg/d)
Number of subjects: 38
Study 24231216 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg/d), saw palmetto (320 mg/d)
Number of subjects: 38
Study 22953318 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 699
Study 22953318 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone added to metformin
Number of subjects: 699
Study 22953318 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with family-based behavioural weight loss programme
Number of subjects: 699
Study 19952577 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (SO, n = 19)
Number of subjects: 36
Study 19952577 — intervention group
Group type: COMPARATOR
Intervention: Running group (RU, n = 17)
Number of subjects: 36
Study 19952577 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 10)
Number of subjects: 36
Study 17538890 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PnCRM7)
Number of subjects: 610
Study 17538890 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose regimen for those 7-11 months of age
Number of subjects: 610
Study 17538890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose regimen for those 12-23 months of age
Number of subjects: 610
Study 15037536 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (anti-TNF-alpha therapy)
Number of subjects: 14
Study 15037536 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment in combination with infliximab
Number of subjects: 14
Study 15037536 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age-matched)
Number of subjects: 14
Study 11813591 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 250 mg q.i.d.
Number of subjects: 648
Study 11813591 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 500 mg b.i.d.
Number of subjects: 648
Study 11813591 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 500 mg b.i.d. plus metronidazole 400 mg b.i.d.
Number of subjects: 648
Study 11813591 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate 400 mg b.i.d. for 14 days after initial treatment
Number of subjects: 648
Study 11813591 — intervention group
Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 648
Study 9726701 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of midazolam at doses of 100, 150, and 200 microg/kg
Number of subjects: 40
Study 9726701 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection of midazolam at a dose of 80 microg/kg
Number of subjects: 40
Study 9726701 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of midazolam at 200 microg/kg
Number of subjects: 40
Study 9726701 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of midazolam
Number of subjects: 40
Study 9726701 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection and i.m. injection of midazolam
Number of subjects: 40
Study 9073056 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 40 mg/m2 + Melphalan (M) 0.4 mg/kg + Cisplatin (C) 50 mg/m2
Number of subjects: 295
Study 9073056 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (A) 40 mg/m2 + Melphalan (M) 0.4 mg/kg
Number of subjects: 295
Study 2309548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16
Study 2309548 — intervention group
Group type: COMPARATOR
Intervention: Fluid load (Control)
Number of subjects: 16
Study 377433 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Makari skin test
Number of subjects: 0
Study 377433 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30677629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic microdebrider adenoidectomy (EMA)
Number of subjects: 60
Study 30677629 — intervention group
Group type: COMPARATOR
Intervention: Curettage adenoidectomy (CA)
Number of subjects: 60
Study 26797134 — intervention group
Group type: EXPERIMENTAL
Intervention: Active beverage containing 361 mg of (poly)phenols and 120 mg of vitamin C, taken twice daily for 4 weeks
Number of subjects: 39
Study 26797134 — intervention group
Group type: EXPERIMENTAL
Intervention: Active beverage
Number of subjects: 39
Study 26797134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no polyphenol/vitamin C)
Number of subjects: 39
Study 24362012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (increased water intake by 1.0-1.5 L/day for 6 weeks)
Number of subjects: 29
Study 24362012 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual water intake)
Number of subjects: 29
Study 21598839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with post-hypnotic suggestion
Number of subjects: 56
Study 21598839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypnosis or suggestion)
Number of subjects: 56
Study 19854321 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (prednisone 50-100 mg equivalent)
Number of subjects: 0
Study 19854321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontapered 5- to 10-day course of corticosteroid therapy
Number of subjects: 0
Study 19854321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of oral and inhaled corticosteroids
Number of subjects: 0
Study 19854321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous corticosteroids, intramuscular and oral corticosteroid regimens
Number of subjects: 0
Study 19854321 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid doses greater than standard doses
Number of subjects: 0
Study 16932832 — intervention group
Group type: EXPERIMENTAL
Intervention: Former elite marathon runners
Number of subjects: 20
Study 16932832 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, gender and BMI)
Number of subjects: 20
Study 15568599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (10 microg/kg/min for 72 hours)
Number of subjects: 68
Study 15568599 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (digitalis, diuretics, ACE-inhibitors)
Number of subjects: 68
Study 11737815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone
Number of subjects: 0
Study 11737815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone-17-valerate
Number of subjects: 0
Study 11737815 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (petrolatum)
Number of subjects: 0
Study 11737815 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study 9357454 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA plus medical treatment
Number of subjects: 62
Study 9357454 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (control group)
Number of subjects: 62
Study 1493945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.5 micrograms/day) for 8 weeks
Number of subjects: 31
Study 1493945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (13 uremic HD patients and 12 healthy subjects)
Number of subjects: 31
Study 3884905 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-platinum
Number of subjects: 23
Study 3884905 — intervention group
Group type: COMPARATOR
Intervention: cis-platinum plus hyaluronidase
Number of subjects: 23
Study 30679283 — intervention group
Group type: EXPERIMENTAL
Intervention: government‐regulated rehabilitation guideline
Number of subjects: 340
Study 30679283 — intervention group
Group type: COMPARATOR
Intervention: preferred‐provider insurance‐based rehabilitation
Number of subjects: 340
Study 30679283 — intervention group
Group type: COMPARATOR
Intervention: education and activation by general practitioners
Number of subjects: 340
Study 30679283 — intervention group
Group type: COMPARATOR
Intervention: general practitioner group
Number of subjects: 340
Study 30679283 — intervention group
Group type: COMPARATOR
Intervention: preferred‐provider group
Number of subjects: 340
Study 30679283 — intervention group
Group type: EXPERIMENTAL
Intervention: all groups
Number of subjects: 340
Study 30672212 — intervention group
Group type: COMPARATOR
Intervention: Cervical plexus block (Control group)
Number of subjects: 40
Study 30672212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical plexus block combined with electroacupuncture (Observation group)
Number of subjects: 40
Study 27336903 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) with continued EGFR-TKI
Number of subjects: 54
Study 27336903 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 54
Study 27336903 — intervention group
Group type: EXPERIMENTAL
Intervention: MWA (complete ablation)
Number of subjects: 54
Study 24398786 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried powdered yacon (FDY) containing 7.4 g of FOS
Number of subjects: 72
Study 24398786 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 72
Study 22500592 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly squeezed orange juice (n=10)
Number of subjects: 30
Study 22500592 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly blended melon juice (n=10)
Number of subjects: 30
Study 22500592 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly squeezed lime juice (n=10)
Number of subjects: 30
Study 19846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 724
Study 19846793 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 724
Study 19846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and/or Insulin
Number of subjects: 724
Study 17902730 — intervention group
Group type: COMPARATOR
Intervention: 5% minoxidil applied twice daily
Number of subjects: 31
Study 17902730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 5% minoxidil and 0.01% tretinoin applied once daily at night
Number of subjects: 31
Study 16234763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5-7.5 mg/day)
Number of subjects: 55
Study 16234763 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (75-100 mg/day)
Number of subjects: 55
Study 12098151 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal condition (both limbs at 100 degrees of knee flexion)
Number of subjects: 20
Study 12098151 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb extended condition (dominant/uninvolved limb at 75 degrees of knee flexion)
Number of subjects: 20
Study 12098151 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb elevated condition (dominant/uninvolved limb on foam support equal to 25% of knee height)
Number of subjects: 20
Study 10101621 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dynorphin A(1-13) (500 micrograms/kg)
Number of subjects: 12
Study 10101621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dynorphin A(1-13) (120 micrograms/kg)
Number of subjects: 12
Study 10101621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7771420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux therapy (three types: two medical therapies and one surgical therapy)
Number of subjects: 247
Study 7771420 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with abnormal baseline PFTs and healed esophagitis
Number of subjects: 247
Study 2342006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g intravenously with induction of anaesthesia)
Number of subjects: 153
Study 2342006 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (three doses of 2 g)
Number of subjects: 153
Study 2342006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 153
Study 2342006 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 153
Study 6242956 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg mane
Number of subjects: 33
Study 6242956 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg nocte
Number of subjects: 33
Study 31947205 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual group (using a radius‐varying sphere)
Number of subjects: 16
Study 31947205 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory group (using a volume‐varying sound)
Number of subjects: 16
Study 31947205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 28169932 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based ultrasound training and clinical training
Number of subjects: 54
Study 28169932 — intervention group
Group type: COMPARATOR
Intervention: Clinical training only
Number of subjects: 54
Study 25444961 — intervention group
Group type: EXPERIMENTAL
Intervention: Group urotherapy (1-hour session)
Number of subjects: 60
Study 25444961 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual urotherapy (15-minute session)
Number of subjects: 60
Study 23803049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a tobacco cessation booklet and four sessions of counselling including a group counselling cum medical camp, followed by proactive counselling through face-to-face (FTF) interview and mobile phone.
Number of subjects: 928
Study 23803049 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling in the second session (4-6 weeks time period).
Number of subjects: 928
Study 23803049 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months.
Number of subjects: 928
Study 23803049 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months (fourth session).
Number of subjects: 928
Study 23803049 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall contact rate in the intervention group.
Number of subjects: 928
Study 21342737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional care during hospitalization and transfer of nutritional care after discharge
Number of subjects: 127
Study 21342737 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional care
Number of subjects: 127
Study 21342737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional care
Number of subjects: 127
Study 19355844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor (ChEI) treatment for 20 weeks
Number of subjects: 26
Study 19355844 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly age-matched controls
Number of subjects: 26
Study 17766527 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral iron supplementation
Number of subjects: 164
Study 17766527 — intervention group
Group type: COMPARATOR
Intervention: Late enteral iron supplementation
Number of subjects: 164
Study 14739496 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (ROM) 2x150 mg/day orally for 4 weeks
Number of subjects: 46
Study 14739496 — intervention group
Group type: COMPARATOR
Intervention: placebo 2x1 tablet/day for 4 weeks
Number of subjects: 46
Study 11552198 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised stretching of the rectus femoris muscle (4 times/week for 2 weeks)
Number of subjects: 29
Study 11552198 — intervention group
Group type: COMPARATOR
Intervention: Calf muscles stretching (control treatment)
Number of subjects: 29
Study 9972406 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated doxorubicin (DOX‐SL) 20‐40mg/m2 administered by intravenous infusion over 30‐60 minutes every two weeks
Number of subjects: 25
Study 9972406 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated doxorubicin (DOX‐SL)
Number of subjects: 25
Study 8147492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms/kg
Number of subjects: 43
Study 8147492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 43
Study 8147492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms/kg
Number of subjects: 43
Study 8147492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (all dosages)
Number of subjects: 43
Study 3130890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1 mg
Number of subjects: 8
Study 3130890 — intervention group
Group type: COMPARATOR
Intervention: Mequitazine 5 mg
Number of subjects: 8
Study 3130890 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg
Number of subjects: 8
Study 3130890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8